Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria

INTRODUCTION: To generalize safety and efficacy findings, it is essential that diverse populations are well represented in Alzheimer's disease (AD) drug trials. In this review, we aimed to investigate participant diversity in disease‐modifying AD trials over time, and the frequencies of partici...

Descripción completa

Detalles Bibliográficos
Autores principales: Franzen, Sanne, Smith, Jade Emily, van den Berg, Esther, Rivera Mindt, Monica, van Bruchem‐Visser, Rozemarijn L., Abner, Erin L., Schneider, Lon S., Prins, Niels D., Babulal, Ganesh M., Papma, Janne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964823/
https://www.ncbi.nlm.nih.gov/pubmed/34590409
http://dx.doi.org/10.1002/alz.12433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964823/
https://www.ncbi.nlm.nih.gov/pubmed/34590409
http://dx.doi.org/10.1002/alz.12433

Ejemplares similares